Welcome to our dedicated page for Wellgistics Health SEC filings (Ticker: WGRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Wellgistics Health, Inc. (NASDAQ: WGRX) SEC filings page on Stock Titan brings together the company’s official disclosures to U.S. regulators, including current reports on Form 8-K, quarterly reports on Form 10-Q, and related exhibits. These documents provide detail on Wellgistics Health’s operations as a pharmacy physical and technology enabling health IT company that connects more than 6,500 pharmacies and over 200 manufacturers through wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services.
Through its filings, Wellgistics has reported material events such as the license agreement with DataVault AI Inc. for intellectual property used to develop its PharmacyChain™ manufacturer-to-patient blockchain-enabled smart contracts platform, sponsorship and licensing arrangements related to Dream Bowl 2026, and debt conversion agreements. Filings also describe the launch and positioning of the EinsteinRx™ pharmacy dispensing optimization AI platform, changes in independent registered public accounting firms, and the reporting of quarterly financial results.
Investors can also review an 8-K describing a Nasdaq notice regarding the company’s minimum bid price deficiency and the associated compliance period, which outlines potential implications for the continued listing of WGRX on The Nasdaq Capital Market. These regulatory documents offer insight into governance, capital structure, strategic partnerships, and risk factors referenced in the company’s public communications.
On Stock Titan, SEC filings for WGRX are supplemented with AI-powered summaries that highlight key terms, financial metrics, and business developments from lengthy documents. Users can quickly identify items related to licensing arrangements, sponsorship agreements, auditor changes, and listing compliance, while still having access to the full text as filed with the SEC. The page also provides convenient access to forms associated with insider and shareholder-related activity when available, helping users track how Wellgistics Health’s regulatory profile evolves over time.
Wellgistics Health, Inc. is soliciting proxies for its virtual Annual Meeting on July 20, 2026 to seek stockholder approval of six proposals, including a corporate name change to DataMeds AI, Inc., authorization of 1,000,000 shares of blank‑check preferred stock, amendments to its equity incentive plan and related issuance of 6,000 shares of super‑voting preferred stock, election of five directors, and ratification of its independent auditor.
The proxy statement discloses governance and compensation details including stockholder record date of June 22, 2026 with 2,647,198 shares outstanding, key executive employment and equity awards (notably a 9,000,000 RSU grant to a former CEO and multi‑million dollar grant values to current executives), committee composition, and beneficial ownership tables. The Board recommends a vote FOR each proposal.
Wellgistics Health, Inc. received an extension from Nasdaq to regain compliance with the stockholders’ equity listing standard after previously reporting stockholders’ equity of $(12,447,801) as of December 31, 2025, below the $2,500,000 minimum. The company is pursuing transactions with DataVault AI and Tollo Health and estimates a potential combined asset value of $4 billion and post-transaction stockholders’ equity of about $40 million.
Nasdaq’s letter allows Wellgistics until October 12, 2026 to demonstrate equity compliance through one of two reporting alternatives that include detailed disclosure and, if used, a pro forma balance sheet evidencing sufficient equity. Separately, Nasdaq confirmed the company has regained compliance with the $1.00 minimum bid price requirement after its common stock closed at or above that level for each business day from May 26, 2026 to June 8, 2026, so that matter is now closed.
Wellgistics Health, Inc. filed an amendment to a prior current report to update a single exhibit. Amendment No. 2 replaces and refiles Exhibit 4.3, described as the Form of Placement Agent Warrant that was previously included with Amendment No. 1. The company states that no other disclosures or exhibits from the original report or Amendment No. 1 are modified, and the amendment does not reflect any subsequent events.
Wellgistics Health, Inc. completed a $21 million convertible debt financing that refinances all of its previously outstanding convertible debt and raises $6.5 million in new capital for operations. The new, oversubscribed instrument does not accrue interest and converts into common shares at $6.00 per share.
The New Debt includes an automatic exchange into a new class of Preferred Stock once a registration statement is effective and stockholders approve the creation of preferred stock. That Preferred Stock converts into common shares at $50.00 per share, and the company notes the transaction may result in substantial future dilution to existing stockholders.
Wellgistics Health, Inc. entered into a financing on May 27, 2026, issuing 0% convertible promissory notes with an aggregate principal amount of $21,132,812.50 for cash proceeds of $16,906,250, reflecting a 20% original issue discount, and accompanying PIPE warrants.
The notes are initially convertible into common stock at the lesser of $6.00 per share or the prior-day closing price, with a $1.00 floor, and will later automatically convert into Series A Convertible Preferred Stock once specified stockholder and charter approvals and a resale registration are effective. PIPE warrants are exercisable at $7.50 per share until May 27, 2031, with total potential gross proceeds of about $42.8 million if all PIPE and placement agent warrants are exercised for cash at initial prices.
The company used part of the proceeds to repay approximately $1.77 million of debt owed to Marco Capital, Inc., and secured lock-up agreements covering 1,333,930 common shares, representing a majority of outstanding shares, restricting sales for at least 90 days under specified conditions.
Wellgistics Health, Inc. released a shareholder letter outlining a major strategic shift toward vertically integrated, blockchain-based healthcare infrastructure. Management explains how recent transactions are meant to connect data, verification, and patient engagement across its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system.
The Company highlights formation of DelivMeds AI and an expanded Datavault license to support tokenized healthcare data, acquisition plans for the QOLPOM patent portfolio to add biometric verification and medical drone capabilities, and a controlling interest in Tollo Health with its Forzet™ offering. Through the Health Lives Here program with NFL Alumni Health, Wellgistics aims to gather real-world GLP-1 patient data that feeds back into its platform.
Wellgistics notes it already connects more than 6,500 pharmacies and 200+ manufacturers and views the pharmacy as a key data and adherence touchpoint. The letter also references a planned share restructuring and new CUSIP and includes extensive forward‑looking statements about revenue expectations, app launch timing, platform integration, and regulatory and execution risks.
Wellgistics Health, Inc. released a shareholder letter outlining a major strategic shift toward vertically integrated, blockchain-based healthcare infrastructure. Management explains how recent transactions are meant to connect data, verification, and patient engagement across its EinsteinRx™ AI platform and PharmacyChain™ smart-contract system.
The Company highlights formation of DelivMeds AI and an expanded Datavault license to support tokenized healthcare data, acquisition plans for the QOLPOM patent portfolio to add biometric verification and medical drone capabilities, and a controlling interest in Tollo Health with its Forzet™ offering. Through the Health Lives Here program with NFL Alumni Health, Wellgistics aims to gather real-world GLP-1 patient data that feeds back into its platform.
Wellgistics notes it already connects more than 6,500 pharmacies and 200+ manufacturers and views the pharmacy as a key data and adherence touchpoint. The letter also references a planned share restructuring and new CUSIP and includes extensive forward‑looking statements about revenue expectations, app launch timing, platform integration, and regulatory and execution risks.
Wellgistics Health, Inc. entered into a fully binding letter of intent with Datavault AI, EOS, Scilex, HealthBridge Advisors and Fortitude Advisors for a multi‑step transaction that would contribute healthcare data, drone logistics and consumer health assets into the company. The parties target an approximate combined asset value of $4.0 billion, subject to an independent fairness opinion and numerous approvals and financing conditions.
The structure would use new preferred stock convertible into common shares so that these counterparties are expected to own about 89.6% of the common stock after conversion, with existing public stockholders retaining about 10.4%, subject to adjustment. Wellgistics also amended a note purchase agreement, increasing the investor’s cash funding to $1.2 million and the related note’s principal to $1.5 million. Separately, the board and stockholders approved a 1‑for‑50 reverse stock split, reducing outstanding shares from roughly 125.7 million to about 2.5 million to help regain Nasdaq minimum bid‑price compliance.
Wellgistics Health, Inc. entered into a fully binding letter of intent with Datavault AI, EOS, Scilex, HealthBridge Advisors and Fortitude Advisors for a multi‑step transaction that would contribute healthcare data, drone logistics and consumer health assets into the company. The parties target an approximate combined asset value of $4.0 billion, subject to an independent fairness opinion and numerous approvals and financing conditions.
The structure would use new preferred stock convertible into common shares so that these counterparties are expected to own about 89.6% of the common stock after conversion, with existing public stockholders retaining about 10.4%, subject to adjustment. Wellgistics also amended a note purchase agreement, increasing the investor’s cash funding to $1.2 million and the related note’s principal to $1.5 million. Separately, the board and stockholders approved a 1‑for‑50 reverse stock split, reducing outstanding shares from roughly 125.7 million to about 2.5 million to help regain Nasdaq minimum bid‑price compliance.
Wellgistics Health, Inc. reported first quarter 2026 results showing rapid revenue growth and a much smaller loss. Wellgistics Pharmacy monthly revenue increased from approximately $0.1 million in November 2025 to approximately $0.6 million in April 2026, based on preliminary unaudited results.
Company revenue was $0.486 million in Q4 2025 and $0.929 million in Q1 2026, and the Company expects revenue of $1.775 million in Q2 2026. Net operating loss narrowed to $7.742 million in the quarter ended March 30, 2026 from $32.430 million a year earlier, with loss per share improving to $0.07 from $0.62.
Management highlighted cost reductions, a Kare Pharmtech joint venture providing access to over 200,000 patient lives, an expanded partnership with Tollo Health, added capabilities such as insurance eligibility verification, and a growing focus on GLP-1 related opportunities and PharmacyChain™/EinsteinRx™ integration.
Wellgistics Health, Inc. reported very weak first-quarter 2026 results, highlighting serious financial strain and Nasdaq listing risks. Net revenues fell to $1.56 million from $10.86 million a year earlier, reflecting a sharp drop in distribution product revenue partly offset by higher pharmacy and logistics sales.
The company posted a net loss of $7.74 million, though this was smaller than the prior-year loss of $32.43 million, and generated a gross profit of only $170,221. Operating expenses were $6.19 million, and net interest expense remained heavy.
As of March 31, 2026, Wellgistics held just $51,730 of cash against $45.19 million of liabilities and a stockholders’ deficit of $15.06 million, prompting management and auditors to state that there is substantial doubt about its ability to continue as a going concern.
During the quarter the company raised $6.5 million of cash through secured convertible notes with an $8.13 million face amount and issued significant equity and warrants to settle compensation and vendor obligations, further diluting shareholders.
Wellgistics also received Nasdaq deficiency notices for failing the $1.00 minimum bid price and the $2.5 million minimum stockholders’ equity requirements. Management is pursuing additional financing, a potential reverse stock split, a new collaboration venture, and proxy proposals to adjust its capital structure, but outcomes remain uncertain.
Wellgistics Health, Inc. filed an 8-K to state that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026 after the market closes. The information is furnished under Regulation FD, meaning it is provided for disclosure purposes and not deemed filed under securities laws.
The company describes itself as a health information technology and pharmaceutical distribution business that integrates its EinsteinRx AI pharmacy optimization platform with its blockchain-enabled PharmacyChain smart contracts platform. This network links more than 6,500 pharmacies and over 200 manufacturers to support distribution, prescription routing, direct-to-patient delivery, and AI-powered hub services.
The accompanying press release also includes forward-looking statements about a proposed acquisition of WellCare Today, LLC and potential integration of remote monitoring and care-coordination technologies, while highlighting numerous regulatory, financing, operational, and reimbursement risks that could cause actual outcomes to differ.